Difference between revisions of "Entospletinib (GS-9973)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= Spleen tyrosine kinase (SYK) inhibitor =Preliminary data= ==CLL== # Sharman...") |
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
||
| Line 5: | Line 5: | ||
==[[Chronic_lymphocytic_leukemia_(CLL)_and_Small_lymphocytic_lymphoma_(SLL)|CLL]]== | ==[[Chronic_lymphocytic_leukemia_(CLL)_and_Small_lymphocytic_lymphoma_(SLL)|CLL]]== | ||
| − | # Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. [http://www.bloodjournal.org/content/125/15/2336.long link to original article] [ | + | # Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. [http://www.bloodjournal.org/content/125/15/2336.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25696919 PubMed] |
[[Category:Drug index]] | [[Category:Drug index]] | ||
Revision as of 03:07, 2 December 2016
Mechanism of action
Spleen tyrosine kinase (SYK) inhibitor
Preliminary data
CLL
- Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. link to original article PubMed